Selective O-GlcNAcase Inhibitors for Tau Hyperphosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for O-GlcNAcase are non-selective, leading to complex phenotypes due to the concomitant inhibition of functionally related enzymes, making it challenging to study the cellular and organismal physiological role of specific enzymes, particularly in treating Alzheimer's disease and related neurodegenerative disorders.
Innovation Solution
Development of specific compounds represented by structural formulas that selectively inhibit O-GlcNAcase, thereby preventing the hyperphosphorylation of tau proteins, which are associated with neurodegenerative diseases such as Alzheimer's and tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition of the target enzyme is achieved, but concomitant inhibition of functionally related enzymes (lysosomal beta-hexosaminidases) occurs, leading to complex phenotypes
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (aromatic rings, heteroatoms, specific substituent patterns) that create localized interactions with the O-GlcNAcase active site. These structural characteristics enable selective binding to O-GlcNAcase while avoiding functionally related enzymes, thereby achieving high selectivity without off-target effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds (substituent types, ring structures, spatial arrangement) to optimize selectivity. By adjusting these chemical parameters, the inhibitors achieve precise fit for O-GlcNAcase while maintaining appropriate spacing and orientation to avoid binding to related enzymes
2Reliability
If existing beta-N-acetylglucosaminidase inhibitors are used, then enzyme function is blocked, but the inhibitors act potently on lysosomal beta-hexosaminidases, complicating physiological studies
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments (aromatic core, heteroatom-containing rings, specific substituent groups) that independently contribute to selectivity. This modular structure allows the inhibitor to engage O-GlcNAcase through multiple localized interactions while avoiding non-specific binding to other enzymes
3Reliability
If O-GlcNAcase is inhibited to prevent tau hyperphosphorylation, then neurodegenerative disease treatment is achieved, but non-selective inhibition causes additional physiological disruptions
Solution Approach 1:
The patent applies the intermediary principle by designing compounds that act as selective mediators between the therapeutic goal (preventing tau hyperphosphorylation) and the biological system. These intermediary molecules achieve the desired therapeutic effect through specific O-GlcNAcase inhibition while their selective binding properties prevent disruption of other physiological pathways
Data Source
AI summary
Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.